Bionano Genomics (BNGO) Projected to Post Earnings on Monday

Bionano Genomics (NASDAQ:BNGO) will likely be issuing its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect Bionano Genomics to announce earnings of ($0.70) per share and revenue of $7.5520 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Bionano Genomics (NASDAQ:BNGO) last announced its earnings results on Wednesday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.12. The business had revenue of $6.69 million for the quarter, compared to analyst estimates of $6.57 million. Bionano Genomics had a negative return on equity of 71.38% and a negative net margin of 109.94%.

Bionano Genomics Stock Up 2.8%

BNGO traded up $0.03 during trading on Monday, hitting $1.10. The company had a trading volume of 113,420 shares, compared to its average volume of 230,149. Bionano Genomics has a 1-year low of $1.00 and a 1-year high of $5.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.84 and a quick ratio of 1.59. The company has a market cap of $12.62 million, a PE ratio of -0.25 and a beta of 1.62. The business has a 50-day moving average of $1.16 and a 200-day moving average of $1.21.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BNGO shares. Wall Street Zen upgraded shares of Bionano Genomics to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bionano Genomics in a research report on Wednesday. Finally, HC Wainwright reduced their target price on shares of Bionano Genomics from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, April 13th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new stake in shares of Bionano Genomics during the 4th quarter valued at $57,000. Carret Asset Management LLC lifted its position in shares of Bionano Genomics by 76.4% in the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after acquiring an additional 19,100 shares in the last quarter. DRW Securities LLC acquired a new position in Bionano Genomics in the 4th quarter worth approximately $258,000. Geode Capital Management LLC grew its position in Bionano Genomics by 148.8% during the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock worth $102,000 after purchasing an additional 39,928 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Bionano Genomics during the 4th quarter valued at $34,000. 11.35% of the stock is owned by institutional investors and hedge funds.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.